Volume 5, Issue 4 (3-2023)                   2023, 5(4): 0-0 | Back to browse issues page

Ethics code: IR.MEDILAM.REC.1400.224

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

najafi G, Anvari E, Ahmadi I, Shahmir P. Evaluion of antibody titer of sinipharm and asterazenca vaccines in a cross-sectional study in ilam. Journal title 2023; 5 (4)
URL: http://newresearch.medilam.ac.ir/article-1-1633-en.html
Department of Physiology, School of Medicine, Ilam University of Medical sciences, Ilam, Iran
Abstract:   (278 Views)
Summary of the necessity of implementing the plan:
Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness, was first reported in Wuhan, the capital of Hubei, China. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a coated virus, belongs to the beta-coronavirus family and contains single-stranded RNA that has been identified as the causative agent of COVID-19. Vaccination is the most effective approach to control the rapid spread of the disease. Antibodies play an important role in creating immunity from vaccination. Numerous studies have shown an association between higher antibody titers and the development of immunity against pathogens. In this study, the immunogenicity and protective effect of Sinopharm and AsteraZeneca vaccines will be evaluated by measuring serum IgG titer against spike protein using Enzyme-Linked Immunosorbent Assay (ELISA), 21 days after the first and second doses.

Forty healthy people, including 20 people receiving the Sinofarm vaccine and 20 people receiving the Astraznica vaccine, are taking part in the study. Alcohol and drug users, people with autoimmune diseases, malignancies, users of immunosuppressive drugs, and people with other underlying diseases will be excluded from the study. The study protocol will be conducted in accordance with the ethical principles of research in Ilam University of Medical Sciences.
Serum IgG concentration against SARS-CoV-2 spike protein will be measured using the purchased kit. Polystyrene microtiter plates are coated with spike protein and serum samples (diluted 1: 100) and positive and negative controls are added to the plate wells in a total volume of 100 μl and the plates are heated to 37 ° C. They are incubated for 30 minutes.
After five washing steps with washing buffer, 50 μl of TMB substrate solution and 50 μl of the corresponding buffer are added and the samples are incubated at 37 ° C for 10 minutes. The reaction was completed by adding 50 μl of 2 M sulfuric acid and the A450 would be measured.


     
: Cross sectional | Subject: General
Received: 2021/09/26 | Accepted: 2021/11/28 | Published: 2023/03/7

Add your comments about this proposal : Your username or Email:
CAPTCHA

Send email to the proposal executer


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Technology and Research Information System

Designed & Developed by : Yektaweb